{"id":68456,"date":"2026-06-23T04:19:12","date_gmt":"2026-06-23T04:19:12","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/68456\/"},"modified":"2026-06-23T04:19:12","modified_gmt":"2026-06-23T04:19:12","slug":"khidi-says-astrazeneca-expands-cooperation-with-korean-biotechs","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/68456\/","title":{"rendered":"KHIDI Says AstraZeneca Expands Cooperation With Korean Biotechs"},"content":{"rendered":"<p><img alt=\"Participants pose for a photo at the &quot;KHIDI-AstraZeneca Project Nova Global Connect&quot; technology cooperation seminar held at the Hilton San Diego Bayfront in San Diego, U.S., on the 22nd (local time). Joint Press Corps - Seoul Economic Daily Culture News from South Korea\" title=\"KHIDI Says AstraZeneca Expands Cooperation With Korean Biotechs\" fetchpriority=\"high\" width=\"1200\" height=\"675\" decoding=\"async\" data-nimg=\"1\" class=\"w-full h-auto rounded-sm\" style=\"color:transparent;object-fit:contain;object-position:center\" src=\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/06\/news-p.v1.20260623.5b524b4b329441f38748c45c346bdd4c_P1.jpg\"\/>Participants pose for a photo at the &#8220;KHIDI-AstraZeneca Project Nova Global Connect&#8221; technology cooperation seminar held at the Hilton San Diego Bayfront in San Diego, U.S., on the 22nd (local time). Joint Press Corps<\/p>\n<p class=\"mb-4 text-[var(--color-text)] leading-relaxed\">The Korea Health Industry Development Institute (KHIDI) and AstraZeneca Korea have created a platform for cooperation to support Korean biotech companies&#8217; entry into global markets.<\/p>\n<p class=\"mb-4 text-[var(--color-text)] leading-relaxed\">KHIDI said it held &#8220;Project Nova Global Connect&#8221; during the BIO International Convention (BIO USA 2026) in San Diego on Monday.<\/p>\n<p class=\"mb-4 text-[var(--color-text)] leading-relaxed\">Project Nova is an open innovation program in which KHIDI and AstraZeneca Korea provide support by connecting the innovative technologies and pipelines of Korean biotech companies with AstraZeneca&#8217;s global headquarters.<\/p>\n<p class=\"mb-4 text-[var(--color-text)] leading-relaxed\">At the event, executives from AstraZeneca&#8217;s technology scouting and evaluation organization attended and held one-on-one partnering meetings with Korean companies. The participating firms discussed possibilities for joint research and commercialization based on technologies in immunology, oncology, and renal and metabolic diseases.<\/p>\n<p class=\"mb-4 text-[var(--color-text)] leading-relaxed\">The event also introduced a cooperation case between Galux, a Korean AI drug discovery company, and biotech venture Ezcuris. Galux was selected as a target company for KHIDI&#8217;s stage-specific technology cooperation acceleration support project and is receiving commercialization funding for its entry into global markets.<\/p>\n<p class=\"mb-4 text-[var(--color-text)] leading-relaxed\">KHIDI plans to continue follow-up support so that the promising pipelines discovered through this partnering can lead to tangible results such as joint research and technology cooperation.<\/p>\n<p class=\"mb-4 text-[var(--color-text)] leading-relaxed\">&#8220;As open innovation is establishing itself as a core strategy of the bio industry, we hope that Project Nova will serve as a bridge for Korean biotechs to enter global markets,&#8221; said Jung Young-hoon, KHIDI&#8217;s planning director. &#8220;We will provide support so that cooperation between global pharmaceutical companies and Korean firms can lead to tangible business results.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"Participants pose for a photo at the &#8220;KHIDI-AstraZeneca Project Nova Global Connect&#8221; technology cooperation seminar held at the&hellip;\n","protected":false},"author":2,"featured_media":68457,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,31834,31836,31838,31839,31833,31837,22730,31835],"class_list":["post-68456","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-astrazeneca-korea","tag-bio-usa-2026","tag-galux","tag-global-market-entry","tag-khidi","tag-korean-biotech","tag-open-innovation","tag-project-nova"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116797503242520565","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/68456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=68456"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/68456\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/68457"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=68456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=68456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=68456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}